Table 1.
Number and proportion of unique continuous statin users and unique continuous statin users exposed to one or several CYP3A4 inhibitors, by year and change
| Statin types | Continuous statin use | Co-medicated with CYP3A4 inhibitors | ||||
|---|---|---|---|---|---|---|
| 2004 | 2006 | Change (between proportions) | 2004 | 2006 | Change (between proportions) | |
| n (%) | n (%) | % | n (%) | n (%) | % | |
| Simvastatin | 112 122 (39.7) | 226 672 (63.1) | 23.4 | 7706 (42.9) | 13 367 (63.6) | 20.7 |
| Lovastatin | 2808 (1.0) | 2017 (0.6) | −0.4 | 285 (1.6) | 186 (0.9) | −0.7 |
| Pravastatin | 39 400 (14.0) | 26 425 (7.4) | −6.6 | 2587 (14.4) | 1776 (8.5) | −5.9 |
| Fluvastatin | 8003 (2.8) | 6627 (1.9) | −1.0 | 402 (2.2) | 370 (1.8) | −0.5 |
| Atorvastatin | 120 051 (42.5) | 97 343 (27.1) | −15.4 | 6997 (38.9) | 5314 (25.3) | −13.6 |
| Total* | 282 384 (100) | 359 084 (100) | 17 977 (100) | 21 013 (100) | ||
*
According to our definition of a continuous statin user, some patients will be able to use more than one statin type during one calendar year. Some patients may therefore be identified as both simvastatin and lovastatin users in Table 1, consequently counted in both places. The summarized number of continuous statin users in each in Table 1 will therefore be higher than in Figure 1 (which shows the number of unique statin users in each group). The Norwegian Prescription Database 2004/2006.